Dr Andorsky on Treatment With Tazemetostat, Lenalidomide, and Rituximab in Follicular Lymphoma

David J. Andorsky, MD, discusses treatment with tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma, highlighting updated outcomes from the phase 1b SYMPHONY-1 trial.

Related Keywords

Davidj Andorsky , ,Mountain Cancer Centers ,Us Oncology Hematology Research ,Treatment With Tazemetostat ,Rocky Mountain Cancer Centers ,Hematology Research ,Ash Annual Meeting And Exposition ,Onclive Tv ,Conference ,